Suraksha Diagnostic IPO Date, Price, GMP, Review, Details, Issue Date, Lot Size, Allotment, Subscription Status
| ➡️ Get instant news updates on Whatsapp. Click here to join our Whatsapp Group. |
Suraksha Diagnostic IPO is set to open on November 29, 2024, and will close on December 3, 2024. This is a Book Built Issue IPO, aiming to raise around ₹846.25 crores. The offering includes a fresh issue and an offer for sale (OFS) of up to 1,91,89,330 equity shares, each with a face value of ₹2.
IPO Highlights
- Price Band: ₹420–₹441 per share
- Lot Size: Minimum 34 shares (₹14,994)
- Issue Type: Book Built
- Listing: BSE & NSE
- Retail Investor Quota: 35%
- QIB Quota: 50%
- HNI Quota: 15%
- Allotment Date: December 4, 2024
- Listing Date: December 6, 2024
Financial Overview
Suraksha Diagnostic has demonstrated strong financial growth:
- FY 2023 Revenue: ₹190.13 crores
- FY 2024 Revenue: ₹218.71 crores (+15% YoY)
- FY 2023 Profit: ₹6.07 crores
- FY 2024 Profit: ₹23.13 crores (+280% YoY)
This reflects consistent profitability and improved margins, making it a promising IPO for long-term investors.
Market Lot Details
Investors can bid for a minimum of 34 shares and a maximum of 442 shares under the retail category.
| Category | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 34 | ₹14,994 |
| Retail Maximum | 13 | 442 | ₹1,94,922 |
| S-HNI Minimum | 14 | 476 | ₹2,09,916 |
| S-HNI Maximum | 66 | 2,244 | ₹9,89,604 |
About the Company
Incorporated in 2005, Suraksha Diagnostic is a leading diagnostic service provider based in East India. Its offerings include pathology and radiology tests, with a robust portfolio of over 2,300 tests, such as advanced biochemistry, molecular pathology, and histopathology.
- Network: 1,522 permanent staff
- CAGR (FY22-24): 20.87% in revenue
- Strengths: Dominance in Eastern India, strong financial performance, and extensive diagnostic solutions.
IPO Objectives
- To carry out the Offer for Sale by selling shareholders.
- To achieve the benefits of listing equity shares on stock exchanges.
Peer Comparison
The company competes with established names such as Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic.
| Company | EPS | PE Ratio | RoNW | NAV |
|---|---|---|---|---|
| Dr. Lal PathLabs | ₹43.05 | 68.66 | 20.35% | ₹221.47 |
| Metropolis Healthcare | ₹24.95 | 82.57 | 12.26% | ₹213.98 |
| Vijaya Diagnostic | ₹11.62 | 67.65 | 19.77% | ₹64.21 |
Important Dates
| Event | Date |
|---|---|
| IPO Open Date | November 29, 2024 |
| IPO Close Date | December 3, 2024 |
| Basis of Allotment | December 4, 2024 |
| Refunds Initiated | December 5, 2024 |
| Credit to Demat | December 5, 2024 |
| Listing Date | December 6, 2024 |
Registrar and Lead Managers
- Registrar: KFin Technologies Limited
- Lead Manager: Nuvama Wealth and Investment Limited
For more details, visit the company’s website: www.surakshanet.com
Disclaimer: Investors are advised to evaluate financial performance, growth prospects, and risks before applying for the IPO.
